S-1: Papa Medical Faces Regulatory Headwinds, IPO Proceeds to Fund Growth

Papa Medical Inc. is proceeding with its initial public offering of 1.5 million Class A common shares at $4.00 per share, aiming to raise $4.95 million, amidst significant regulatory changes impacting its core Delta-8 THC product line and recent declines in profitability.

Summary

• Papa Medical Inc. is offering 1,500,000 shares of Class A common stock at an estimated initial public offering price of US$4.00 per share, with an option for underwriters to purchase an additional 225,000 shares.
• The company expects to receive net proceeds of approximately US$4,949,000 from the offering, assuming no exercise of the over-allotment option.
• Proceeds are allocated as follows: 30.0% (US$1,484,700) for R&D, 30.0% (US$1,484,700) for plant and facilities upgrades, 25.0% (US$1,237,250) for sales and marketing, and 15.0% (US$742,350) for working capital and general corporate purposes.
• A new federal law, the 2026 Federal Appropriations Bill, signed on November 12, 2025, will reclassify Delta-8 THC products as Schedule 1 marijuana, prohibiting their sale after November 12, 2026.
• Revenues from 'Future Excluded Products' (Delta-8 THC) accounted for 31.9% of total revenues for the nine months ended September 30, 2025, and 29.5% for the year ended December 31, 2024.
• For the nine months ended September 30, 2025, total revenues increased by 46.4% to US$39.9 million from US$27.3 million in the prior year period, driven by expansion in Hemp cannabinoid E-vapors.
• However, for the three months ended September 30, 2025, total revenues decreased by 26.1% to US$7.4 million from US$10.0 million in the prior year period, primarily due to new regulations on product packaging.
• Net income for the nine months ended September 30, 2025, decreased by 43.7% to US$0.6 million from US$1.0 million in the prior year period.
• The company reported a net loss of US$0.8 million for the three months ended September 30, 2025, compared to a net income of US$0.3 million for the same period in 2024.
• Cash used in operating activities was US$3.3 million for the nine months ended September 30, 2025, a significant increase from US$0.7 million used in the prior year period.
• Mr. Jian Hua, CEO and director, holds 96.57% of the company's outstanding voting power, making it a controlled company under Nasdaq listing rules.
• The company relies on related parties, primarily Shenzhen Feellife (controlled by Mr. Hua), for technology R&D, marketing, financial expertise, and production management, with significant transactions recorded.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant regulatory changes that will prohibit a substantial portion of current revenue (31.9% of total revenue) starting November 2026. Recent financial performance shows a concerning decline in net income and operating income, with a shift to net loss in the most recent quarter and increased cash burn from operations. While the IPO provides capital and the company has innovative technologies and growth strategies, the immediate and material regulatory headwind, coupled with deteriorating profitability, presents substantial challenges and uncertainty.

Positives

• Total revenues increased by 49.0% from US$25.3 million in FY2023 to US$37.7 million in FY2024, and by 46.4% to US$39.9 million for the nine months ended September 30, 2025, compared to US$27.3 million in the prior year period.
• Gross profit increased by 46.5% from US$6.4 million in FY2023 to US$9.4 million in FY2024, and by 33.8% to US$9.1 million for the nine months ended September 30, 2025, compared to US$6.8 million in the prior year period.
• The company possesses innovative atomization (AiMesh) and aroma molecule blending (feelmixX) technologies, facilitating precise dosing and enhanced user experience in E-vapors.
• Identified as one of the few end-to-end innovative Hemp dosing solution providers in the US with a medical atomization/nebulizing background and engaging in No Heat No Burn (NHNB) technology.
• Strategic growth plans include global expansion, R&D innovation, diversification into medical products, and scaling up production capacity.
• The company has applied for listing on the Nasdaq Capital Market under the symbol PAPA, which would provide public market access.

Negatives

• The 2026 Federal Appropriations Bill will prohibit the sale of Delta-8 THC products after November 12, 2026, which accounted for 31.9% of total revenues for the nine months ended September 30, 2025, and 29.5% for FY2024, posing a material adverse effect on future revenues.
• Net income decreased by 43.7% to US$0.6 million for the nine months ended September 30, 2025, from US$1.0 million in the prior year period.
• The company reported a net loss of US$0.8 million for the three months ended September 30, 2025, compared to a net income of US$0.3 million for the same period in 2024.
• Operating income decreased significantly, from US$1.5 million for the nine months ended September 30, 2024, to US$0.6 million for the nine months ended September 30, 2025.
• Cash used in operating activities increased substantially to US$3.3 million for the nine months ended September 30, 2025, from US$0.7 million in the prior year period.
• Gross profit margin decreased to 22.7% for the nine months ended September 30, 2025, from 24.8% in the prior year period, attributed to volume-related cost increases and product mix adjustments.
• Selling and marketing expenses increased by 60.6% to US$5.3 million for the nine months ended September 30, 2025, partly due to US$0.7 million in Amazon platform fees.
• General and administrative expenses increased by 48.8% to US$2.2 million for the nine months ended September 30, 2025, due to increased labor costs, property insurance, decoration, depreciation, taxes, and legal fees.
• Research and development expenses increased by 86.9% to US$1.0 million for the nine months ended September 30, 2025, due to increased personnel and activities for new E-vapors.
• Significant customer concentration, with two customers collectively representing 66.8% of total revenues for the nine months ended September 30, 2025, and 56.7% for FY2024.
• Significant supplier concentration, with three suppliers accounting for 38.9% of total purchases for the nine months ended September 30, 2025, and four suppliers accounting for 78.9% of accounts payable as of September 30, 2025.
• Extensive related party transactions with entities controlled by the CEO, raising potential conflict of interest concerns and reliance risks.

Risks

• Enaction of certain provisions under the 2026 Federal Appropriations Bill will materially and adversely affect business operations by reclassifying Delta-8 THC products as Schedule 1 marijuana, prohibiting sales after November 12, 2026.
• State-level regulation of hemp products is rapidly developing and changes to enforcement priorities could negatively impact the business.
• Existing and new laws, regulations, policies, and restrictions in the E-vapors and/or Hemp cannabinoid vapor industry can materially and adversely affect business operations.
• The FDA could change its enforcement priorities with respect to cannabis and hemp-derived products, potentially classifying them as unapproved drugs.
• Products could be subject to product liability legal claims as a result of adverse events, including long-term health risks associated with E-vapors.
• Legal proceedings alleging violations of the Federal Paraphernalia Law or changes in its interpretation could adversely affect the business.
• Mr. Jian Hua, CEO and director, holds 96.57% of common stock and 70.0% of a related party, creating potential conflicts of interest.
• Exposure to risks relating to relationships with certain related parties, including reliance on Shenzhen Feellife for critical services.
• Legislation and regulations relating to delivery, sales, and shipping restrictions of tobacco products (like the PACT Act) may make it more difficult to sell Hemp cannabinoid E-vapors and consuming E-vapors in the United States.
• The E-vapors market may develop more slowly or differently than expected due to uncertainties in acceptance, health studies, economic conditions, and regulatory landscape.
• Intense competition from companies in the E-vapors industry and other sources of nicotine and Hemp.
• Business, financial condition, and results of operations may be adversely impacted by product defects or other quality issues, leading to recalls or reputational damage.
• Limited insurance coverage could expose the company to significant costs and business disruption from liability claims.
• Inability to develop and introduce new products or upgrade existing products in a timely and cost-effective manner.
• Misconduct, including illegal, fraudulent, or collusive activities, by employees, customers, suppliers, and manufacturers may harm brand and reputation.
• Cyber-attacks and security vulnerabilities could result in serious harm to reputation, business, and financial condition, as evidenced by a recent ransomware incident at a representative.
• Substantially all executive officers and directors are located in mainland China, making it difficult to effect service of process or enforce U.S. judgments.
• Uncertainties in the interpretation and enforcement of PRC laws and regulations may limit or hinder the ability to offer shares or cause their value to decline.
• Potential subjection to governmental regulations, legal obligations, and liability related to privacy, information security, and data protection (e.g., California Privacy Law, GDPR).
• Infringement claims relating to intellectual properties of third parties may be expensive to defend and disrupt business.
• Inability to manage growth or execute strategies effectively could materially and adversely affect business and prospects.
• Dependence on the continued contributions of senior management and other key personnel.
• Joel Adalberto Gallo, an independent director candidate, is a co-defendant in a securities class action lawsuit.
• Competition for highly skilled employees is intense.
• Any global systemic economic and financial crisis could negatively affect business, results of operations, and financial condition.
• Internal control over financial reporting may not be effective, and deficiencies could have a material adverse effect.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to a small public offering and large insider holdings.
• As a controlled company under Nasdaq rules, the company may not comply with certain corporate governance requirements, reducing shareholder protection.
• Undetermined specific use for a portion of net IPO proceeds, allowing management discretion.
• No expectation of paying dividends in the foreseeable future, requiring reliance on stock price appreciation for investment return.
• Increased costs as a result of being a public company.
• If securities or industry analysts cease to publish research or reports, or if they adversely change recommendations, the market price and trading volume could decline.

Future Outlook

The company plans to mitigate the material adverse effect of the 2026 Federal Appropriations Bill by implementing strategies of global expansion into new regional markets and diversification by exploring the medical products sector. It intends to continue offering and selling 'Future Excluded Products' (Delta-8 THC) until November 12, 2026, after which any remaining products will be destroyed. The company expects its selling and marketing expenses to continue to increase in absolute dollars as it expands its sales force and presence. Research and development expenses are also expected to vary as a percentage of revenue.

Management Comments

• We believe our full-cycle operations and leading market position will position us to further capitalize on the growth potential of the US Hemp cannabinoid E-vapors market.
• We are still evaluating impacts resulting from the regulatory change and our development strategies during the grace period contained under the 2026 Federal Appropriations Bill.
• We plan to continue offering and selling the Future Excluded Products prior to November 12, 2026. After its effectiveness on November 12, 2026, we plan to continue offering and selling Hemp products that are not Future Excluded Products.
• We plan to implement our strategies of global expansion into new regional markets and diversification by exploring medical products section, in order to mitigate material adverse effect on our business resulting from the regulatory change.

Industry Context

The U.S. Hemp cannabinoid E-liquid industry grew from US$879.9 million in 2020 to US$3,057.6 million in 2024 (CAGR of 36.5%) and is projected to reach US$8,890.5 million by 2029 (CAGR of 22.3%). The U.S. Hemp cannabinoid E-vapor market grew from US$502.8 million in 2020 to US$1,528.8 million in 2024 (CAGR of 32.1%) and is expected to grow to US$3,232.9 million by 2029 (CAGR of 15.0%). The end-to-end Hemp dosing solution industry in the US surged from US$1,728.4 million in 2020 to US$5,733.0 million in 2024 (CAGR of 35.0%) and is projected to reach US$15,154.3 million by 2029 (CAGR of 20.1%). The U.S. nebulizer market grew from US$1.7 billion in 2020 to US$2.6 billion in 2024 (CAGR of 12.1%) and is expected to grow to US$4.5 billion by 2029 (CAGR of 11.7%). Papa Medical operates in a fragmented and highly competitive Hemp dosing industry with over 400 participants, positioning itself as an end-to-end innovative provider with medical atomization background and NHNB technology. Regulatory clarity and broadening applications beyond recreation are key market drivers, while technology, supply chain, qualification, and brand are significant entry barriers.

Comparison to Industry Standards

• The company is identified as the first end-to-end innovative Hemp dosing solution provider in the US that possesses a medical atomization or nebulizing background and sells nebulizers, suggesting a first-mover advantage in this niche.
• The company is one of the few end-to-end innovative Hemp dosing solution providers in the US that engage in the revolutionization of healthier nicotine ingestion experience with No Heat No Burn (NHNB) technology, according to the Frost & Sullivan Report, indicating a competitive edge in advanced technology.
• The company's full-cycle operations and leading market position are believed to enable it to stand out in the Hemp cannabinoid E-vapors and consuming E-vapors markets, implying a competitive advantage over traditional vaping corporations.

Management Changes

Corporate Governance

Legal Proceedings

• Joel Adalberto Gallo, an independent director candidate, is a co-defendant in a securities class action lawsuit filed in March 2024 in the Supreme Court of the State of New York for the County of New York (Daniel Perrier v. Hywin Holdings Ltd., et al.). The lawsuit alleges violations of the Securities Act of 1933 related to alleged misstatements or omissions in offering documents concerning Hywin Holdings Ltd.'s exposure to financially distressed real estate developers. The settlement has been finalized and approved, and the matter is not expected to materially impact Mr. Gallo's ability to serve or the company's business.
• The company is not a party to any material legal or administrative proceedings as of the date of the prospectus.

Related Party Transactions

• The company has a business process outsourcing service agreement with Shenzhen Feellife (controlled by CEO Mr. Jian Hua), effective from January 1, 2022, to December 31, 2026, for technology R&D, marketing, financial expertise, production management, and business process design and operation.
• Purchases from Shenzhen Feellife amounted to US$2,271,778 for the nine months ended September 30, 2025, and US$4,186,353 for the year ended December 31, 2024.
• Service expenses paid to Shenzhen Feellife amounted to US$1,891,259 for the nine months ended September 30, 2025, and US$2,240,245 for the year ended December 31, 2024.
• Amounts due to Shenzhen Feellife were US$3,884,798 as of September 30, 2025, and US$4,826,976 as of December 31, 2024, including transferred net balances from twelve other related parties for centralized management and settlement.
• The company has a lease agreement with Cpresso, LLC (controlled by Shenzhen LFS, which is controlled by CEO Mr. Jian Hua), effective from January 1, 2021, to December 31, 2026, for a real estate property in California.
• Rental expenses paid to Cpresso, LLC amounted to US$339,750 for the nine months ended September 30, 2025, and US$96,000 for the year ended December 31, 2024. Lease rates with Cpresso, LLC are currently more favorable than market rates and are expected to be adjusted to market rates from January 1, 2025.
• The CEO, Mr. Jian Hua, directly and indirectly owns 70.0% of the equity in Shenzhen Feellife, and has significant input on pricing and business decisions with this related party.

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution from the IPO. The dual-class share structure and controlled company status limit influence on corporate matters. The prohibition of Delta-8 THC products will materially and adversely affect future revenues and potentially the stock price. Investment return relies solely on price appreciation as no dividends are expected.
• Employees: Potential impact from labor shortages, inflation, and supply chain vulnerabilities. Competition for highly skilled employees is intense. Misconduct by employees could harm brand and reputation.
• Customers: Impacted by new regulations on product packaging and the upcoming prohibition of Delta-8 THC products. The company's ability to meet evolving preferences and maintain product quality is crucial for customer retention.
• Suppliers: Concentration risks with major suppliers could lead to supply disruptions and price volatility. Reliance on related party suppliers (Shenzhen Feellife) creates interdependence.
• Regulatory Authorities: Increased scrutiny due to involvement in the Hemp product industry, with evolving federal and state regulations (e.g., 2026 Federal Appropriations Bill, FDA, DEA, FTC, PACT Act) posing compliance challenges and potential enforcement actions.

Next Steps

• Continue offering and selling 'Future Excluded Products' (Delta-8 THC) until November 12, 2026.
• Destroy any remaining 'Future Excluded Products' prior to November 12, 2026.
• Implement strategies of global expansion into new regional markets.
• Diversify by exploring the medical products sector.
• Enhance production capacity and diversify product offerings through a comprehensive upgrade of CANNAPRESSO LAB INC.
• Apply for and obtain Nasdaq listing for Class A common stock under the symbol PAPA.
• Continue R&D efforts for new E-vapors, such as the iPrefer series.

Key Dates

Recommendation

The company faces a severe and imminent regulatory threat with the 2026 Federal Appropriations Bill, which will prohibit the sale of Delta-8 THC products, representing nearly one-third of its current revenue, starting November 2026. This creates significant uncertainty and a material adverse effect on future financial performance. Recent financial results show a concerning trend of declining net income and operating income, with the most recent quarter reporting a net loss and increased cash burn from operations. While the IPO provides capital, the underlying business fundamentals are deteriorating, and the long-term viability of a substantial portion of its product line is compromised. The high concentration of voting power with the CEO and extensive related-party transactions also present governance risks. Given these substantial headwinds and the negative financial trajectory, a seasoned investor would likely recommend selling or avoiding this stock.

Keywords

Hemp cannabinoid E-vapors, E-vapors, Medical nebulizers, IPO, SEC filing, Delta-8 THC, Regulatory risk, AiMesh technology, feelmixX technology, No Heat No Burn (NHNB), ODM, Nasdaq Capital Market, Controlled company, Related party transactions, Financial performance, Growth strategies, Cannapresso, Biotechnology, Medical devices